Neutrophils as potential therapeutic targets in hepatocellular carcinoma
The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …
Neutrophils: Driving inflammation during the development of hepatocellular carcinoma
H Chen, XH Zhou, JR Li, TH Zheng, FB Yao, B Gao… - Cancer Letters, 2021 - Elsevier
The relationship between immune and inflammatory responses in hepatocellular carcinoma
(HCC) has garnered significant interest. In the peripheral blood and tumour …
(HCC) has garnered significant interest. In the peripheral blood and tumour …
[HTML][HTML] Tumor-associated neutrophils in hepatocellular carcinoma pathogenesis, prognosis, and therapy
Simple Summary Hepatocellular carcinoma is the most prevalent primary liver cancer,
accounting for> 80% of primary liver cancers worldwide. Inflammation has come to light as a …
accounting for> 80% of primary liver cancers worldwide. Inflammation has come to light as a …
[HTML][HTML] Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?
Background: Irrespective of the underlying aetiology, 90% of hepatocellular carcinomas
arise and progress on a background of chronic inflammation. We have explored the …
arise and progress on a background of chronic inflammation. We have explored the …
[HTML][HTML] Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus …
Simple Summary Immunotherapy is now the standard front-line therapy for patients with
advanced hepatocellular carcinoma. However, there remains a substantial proportion of …
advanced hepatocellular carcinoma. However, there remains a substantial proportion of …
[PDF][PDF] Myeloid cells in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is highly associated with inflammation. Myeloid cells,
including tumor‐associated macrophages and myeloid‐derived suppressor cells, are …
including tumor‐associated macrophages and myeloid‐derived suppressor cells, are …
[HTML][HTML] Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib
SL Zhou, ZJ Zhou, ZQ Hu, XW Huang, Z Wang… - Gastroenterology, 2016 - Elsevier
Background & Aims Neutrophils can either promote or inhibit tumor progression, depending
on the tumor microenvironment, via release of cytokines. Neither the factors produced by …
on the tumor microenvironment, via release of cytokines. Neither the factors produced by …
Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a …
T Tada, T Kumada, A Hiraoka, M Hirooka… - European Journal of …, 2022 - journals.lww.com
Objective: To investigate whether neutrophil-to-lymphocyte ratio (NLR) can predict outcomes
in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab …
in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab …
Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma
DM Kuang, Q Zhao, Y Wu, C Peng, J Wang, Z Xu… - Journal of …, 2011 - Elsevier
BACKGROUND & AIMS: Substantial evidence indicates that inflammation is a critical
component of tumor progression. Hepatocellular carcinoma (HCC) is usually derived from …
component of tumor progression. Hepatocellular carcinoma (HCC) is usually derived from …
[HTML][HTML] Hepatocellular carcinoma immune landscape and the potential of immunotherapies
Hepatocellular carcinoma (HCC) is the most common liver tumor and among the deadliest
cancers worldwide. Advanced HCC overall survival is meager and has not improved over …
cancers worldwide. Advanced HCC overall survival is meager and has not improved over …